News Release

ESMO Sarcoma and Rare Cancers 2024: Event announcement

Lugano, Switzerland, 14-16 March

Meeting Announcement

European Society for Medical Oncology

Lugano, Switzerland, 6 March 2024 – The ESMO Sarcoma and Rare Cancers Congress 2024 will be held in Lugano from 14 to 16 March and will bring together world-renowned experts among researchers and practitioners, to present and discuss the latest advances in the treatment and care of sarcoma and rare cancers in general. They will provide in-depth perspectives on current and new approaches to research, targeted therapies, precision medicine, methodological challenges, policy and guidelines that touch on the predominant issues and needs in the field. Participation is onsite only. 

The scientific and educational programme is available online to help you navigate the richness of sessions. 


Programme highlights 

  • Novel approaches in the treatment of advanced refractory sarcoma and soft tissue sarcoma.  

  • Further evidence on continued treatment with imatinib in patients with localized GIST at high risk of relapse and advanced GIST. 

  • New insights into natural history, biology and treatment of rare malignancies. 

  • New data confirming impact of rare tumors on health-related quality of life and improvement in quality of life with novel therapies in desmoid tumors. 

  • Debate on the centralisation of care in national and international reference networks for rare cancers, access to treatment and clinical trials, the patients’ diagnostic journey and policies. 

The results of 149 studies will be presented and published online as a supplement to ESMO Open. 

Press accreditation 

ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities. To apply for press accreditation, please fill out the form available here. Requests for press accreditation should be sent by Wednesday, 13 March. Please be kindly informed that onsite press accreditation will not be possible. 


Further information 

ESMO Press Office 


Notes to editors 

Please make sure to use the official name of the meeting in your reports: ESMO Sarcoma and Rare Cancers Congress 2024 and the official congress hashtag #ESMOSarcomaAndRareCancers24. Follow it to stay up to date and use it to take part in the conversation on X (Twitter), LinkedIn, Facebook, Instagram, YouTube. 


About the European Society for Medical Oncology (ESMO)   

Representing more than 35,000 oncology professionals from 172 countries worldwide, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE.    










Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.